2022 MIPS IA_PSPA_6: Consultation of the Prescription Drug Monitoring program

Activity ID


Activity Weighting


Subcategory Name

Patient Safety and Practice Assessment

Activity Description

Review the history of controlled substance prescriptions for 90 percent* of patients using state prescription drug monitoring program (PDMP) data prior to the issuance of a Controlled Substance Schedule II (CSII) opioid prescription lasting longer than 3 days. *Apply exceptions for patients receiving palliative and hospice care.


Use patients' past prescription history to inform decisions about issuing new controlled substance schedule II opioid prescriptions, thus identifying and protecting patients who are at risk of opioid addition and/or overdose.

Suggested Documentation

Evidence of prescription drug monitoring program (PDMP) consultation before issuance of a controlled substance schedule II (CSII) opioid prescription that lasts longer than 3 days. Include both of the following elements, for the same time period:

1) Number of issuances of CSII Prescription – Total number of issuances of a CSII prescription that lasts longer than 3 days (e.g., screenshot or report from PDMP web portal displaying data); AND
2) Documentation of consulting the PDMP – Total number of patients for which there is evidence of consulting the PDMP prior to issuing an CSII prescription (e.g., copies of patient reports created with the Protected Health Information masked, PDMP website screenshot); AND
3) Documentation for exceptions – Total number of patients receiving hospice and palliative care, and who are exempt from Centers for Disease Control and Prevention (CDC) prescribing guidelines.

Register with MDinteractive